Disease · MONDO_0013282
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| MMF - Cystic Fibrosis vs MMF - COPD, Emphysema, IPF, or A1AD: serious adverse events | 13 of 33 | 14 of 35 | 68 | NCT01014442 | Trial comparisons |
| Liquid Alpha₁-PI vs Prolastin-C: serious adverse events | 0 of 32 | 1 of 31 | 63 | NCT02282527 | Trial comparisons |
| Alvelestat (MPH966) vs Placebo: Numbers and % of Subjects Who Experience at Least 1 Treatment-emergent Adverse Event | 25 of 32 | 23 of 31 | 63 | NCT03679598 | Trial comparisons |
| Alvelestat (MPH966) vs Placebo: deaths from any cause | 0 of 32 | 0 of 31 | 63 | NCT03679598 | Trial comparisons |
| Alvelestat (MPH966) vs Placebo: serious adverse events | 0 of 32 | 0 of 31 | 63 | NCT03679598 | Trial comparisons |
| 60 mg/kg Prolastin-C vs 120 mg/kg Prolastin-C: Subjects Withdrawn Due to an AE(s) | 0 of 30 | 0 of 30 | 60 | NCT01213043 | Trial comparisons |
| 60 mg/kg Prolastin-C vs 120 mg/kg Prolastin-C: Subjects With Treatment-Emergent Pulmonary Exacerbation(s) | 7 of 30 | 5 of 30 | 60 | NCT01213043 | Trial comparisons |
| 60 mg/kg Prolastin-C vs 120 mg/kg Prolastin-C: Subjects With Severe TEAE(s) or Pulmonary Exacerbation(s) | 0 of 30 | 0 of 30 | 60 | NCT01213043 | Trial comparisons |
| 60 mg/kg Prolastin-C vs 120 mg/kg Prolastin-C: Subjects With Drug-Related TEAE(s) | 3 of 30 | 1 of 30 | 60 | NCT01213043 | Trial comparisons |
| 60 mg/kg Prolastin-C vs 120 mg/kg Prolastin-C: Subjects With Treatment-Emergent Serious Adverse Events (SAEs) | 0 of 30 | 0 of 30 | 60 | NCT01213043 | Trial comparisons |
| 60 mg/kg Prolastin-C vs 120 mg/kg Prolastin-C: Subjects With Treatment-Emergent Adverse Events (TEAEs) | 23 of 30 | 18 of 30 | 60 | NCT01213043 | Trial comparisons |
| 60 mg/kg Prolastin-C vs 120 mg/kg Prolastin-C: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT01213043 | Trial comparisons |
| ARALAST Fr. IV-1 vs ARALAST: serious adverse events | 0 of 25 | 0 of 25 | 50 | NCT00242385 | Trial comparisons |
| Liquid Alpha₁-PI/Prolastin-C vs Prolastin-C/Liquid Alpha₁-PI: Number of Subjects With Immunogenicity Response | 0 of 16 | 0 of 16 | 32 | NCT02282527 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0013282/comparisons